• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Real-world prescribing of lecanemab in the United States

Real-world prescribing of lecanemab in the United States

by Truveta Research | May 6, 2024 | Research, Research Insights

Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl, PhD ⊕Truveta, Inc, Bellevue, WA, Charlotte Baker, DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD PhD...
Real-world trends in APOE genetic testing associated with lecanemab

Real-world trends in APOE genetic testing associated with lecanemab

by Truveta Research | Nov 10, 2023 | Research, Research Insights

Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023. A potential side effect of the drug is brain swelling and/or small hemorrhages and is most common for people with the APOE ε4 genetic variant, therefore rates of APOE e4...

Share this


Recent posts

  • How Truveta benchmarks AI model quality for clinical concept extraction
  • Truveta Data analysis shows improved outcomes with Impella support in high-risk heart procedures
  • Evaluating recent trends in early measles vaccinations in Texas

Follow Truveta


Sign up for our newsletter

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice